Mounjaro and Heart Failure: What the SUMMIT Trial Shows

Heart failure and obesity are closely intertwined conditions, each one worsening the other in ways that make treatment challenging. Excess body weight places additional strain on the heart, promotes chronic inflammation, and accelerates the structural changes that lead to cardiac dysfunction. For many patients living with obesity-related heart conditions, the question of whether weight-loss medications could offer meaningful cardiovascular benefit has remained largely unanswered.

That changed with the SUMMIT trial, a large-scale clinical study examining whether tirzepatide, the active ingredient in Mounjaro, could improve outcomes in patients with a specific form of heart failure strongly linked to obesity. The results, presented at the American Heart Association Scientific Sessions in 2024 and published in the New England Journal of Medicine, provide the strongest evidence to date that treating obesity may directly improve heart failure outcomes.

Heart failure is often misunderstood as a condition in which the heart stops beating entirely. In reality, it describes a state in which the heart cannot pump blood efficiently enough to meet the body’s demands. There are two main types. In heart failure with reduced ejection fraction (HFrEF), the heart muscle becomes weak and cannot contract forcefully enough. In heart failure with preserved ejection fraction (HFpEF), the heart pumps with normal strength, but the muscle has become stiff and cannot relax properly between beats. This stiffness means the heart chambers do not fill with blood as they should, leading to a backlog of pressure that causes fluid to accumulate in the lungs and other tissues.

HFpEF accounts for roughly half of all heart failure cases, and its prevalence is rising. It is strongly associated with obesity, type 2 diabetes, and hypertension, conditions that together drive the structural remodelling of the heart. Patients with HFpEF typically experience breathlessness on exertion, persistent fatigue, ankle swelling, and a marked reduction in exercise tolerance. These symptoms can be profoundly disabling, yet until recently there were few effective treatments specifically targeting HFpEF. Most heart failure therapies were developed for HFrEF and have shown limited benefit in the preserved ejection fraction population.

SUMMIT stands for Study Using Tirzepatide in Participants with HFpEF and Obesity. It was a randomised, double-blind, placebo-controlled trial registered under the identifier NCT04847557, designed to test whether tirzepatide could improve cardiovascular outcomes in patients living with both HFpEF and obesity.

The trial enrolled 731 participants, all of whom had a confirmed diagnosis of HFpEF and a body mass index of 30 or above. Participants were randomly assigned to receive either weekly subcutaneous injections of tirzepatide, titrated up to a maximum dose of 15 mg, or a matching placebo. Treatment continued for up to 104 weeks, providing a substantial follow-up period to assess both efficacy and safety.

The primary composite endpoint combined two key outcomes: cardiovascular death and worsening heart failure events. Secondary endpoints included changes in heart failure symptoms, exercise capacity, and body weight. The trial’s design was rigorous, and its results were closely watched by both the cardiology and obesity medicine communities.

The headline finding from SUMMIT was a 38% reduction in the composite of cardiovascular death or worsening heart failure events among participants receiving tirzepatide compared to placebo, corresponding to a hazard ratio of 0.62. This is a clinically significant result, particularly for a condition that has historically been difficult to treat.

Beyond the primary endpoint, tirzepatide produced meaningful improvements across a range of secondary measures. The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), a well-validated tool for measuring heart failure symptoms and quality of life, improved by 6.9 points in the tirzepatide group compared to placebo. This exceeds the 5-point threshold that is generally recognised as clinically meaningful, indicating that patients genuinely felt better in their daily lives.

Exercise capacity also improved, as measured by the 6-minute walk distance, a standard assessment in heart failure trials. Participants taking tirzepatide were able to walk further, reflecting better functional status and reduced symptom burden during physical activity.

The metabolic and structural cardiac effects were equally noteworthy. Mean weight loss in the tirzepatide group was approximately 13 to 15%, consistent with what has been observed in other tirzepatide trials. Left ventricular mass decreased by 11 grams, suggesting a reversal of some of the pathological cardiac remodelling associated with obesity. Paracardiac adipose tissue, the fat deposits that surround the heart and impair its ability to expand and relax, was reduced by 45 millilitres. Markers of systemic inflammation also declined, pointing to broader improvements in the metabolic environment that drives cardiac dysfunction.

The cardiovascular benefits observed in SUMMIT are likely to result from several overlapping mechanisms rather than a single pathway. The most straightforward is weight reduction itself. Excess body weight increases blood volume, raises cardiac filling pressures, and forces the heart to work harder with every beat. Losing a significant amount of weight relieves this mechanical load, allowing the heart to function more efficiently.

Reduced systemic inflammation is another important factor. Obesity is associated with chronic, low-grade inflammation that damages blood vessel linings and promotes the stiffening of cardiac tissue. By reducing fat mass and improving metabolic health, tirzepatide appears to lower circulating inflammatory markers, which in turn may improve endothelial function and reduce the progression of cardiac fibrosis.

Lower blood pressure also plays a role. Hypertension is one of the primary drivers of left ventricular hypertrophy and diastolic dysfunction, the hallmarks of HFpEF. Mounjaro also lowers blood pressure, and this reduction in afterload decreases the workload placed on the heart over time.

The dramatic reduction in paracardiac fat observed in SUMMIT is particularly relevant to HFpEF. Fat deposits around the heart physically constrain the pericardium and limit the heart’s ability to fill during diastole. Removing this fat improves cardiac compliance, allowing the chambers to expand more freely and fill with blood more effectively. Finally, improved insulin sensitivity and metabolic health contribute to better overall cardiovascular function, as insulin resistance is increasingly recognised as an independent driver of cardiac disease.

The SUMMIT trial specifically enrolled patients with a BMI of 30 or above and a confirmed diagnosis of HFpEF, so the evidence applies most directly to this population. Patients who experience breathlessness on exertion, exercise intolerance, and fluid retention alongside significant excess weight may be the group most likely to benefit from tirzepatide’s combined weight loss and cardiovascular effects.

It is important to note, however, that Mounjaro is not currently licensed for the treatment of heart failure in the United Kingdom. Its approved indications are weight management (in patients meeting specific BMI criteria) and type 2 diabetes. Any use of tirzepatide specifically to treat HFpEF would be considered off-label and should only be considered with specialist cardiology input. This is not a decision that patients should make independently or without the involvement of their heart failure team.

CutKilo prescribes Mounjaro for weight loss under medical supervision. Patients with known heart conditions are reviewed individually, and treatment decisions take into account the full clinical picture, including any cardiac diagnoses, current medications, and specialist recommendations. The SUMMIT data are encouraging, but they do not change the regulatory status of the medication or the need for careful clinical oversight.

While the SUMMIT results are compelling, several limitations should be kept in mind. The trial studied a very specific population: patients with HFpEF and obesity. The findings should not be extrapolated to patients with heart failure with reduced ejection fraction (HFrEF), which has a different underlying pathology and responds to different treatments. Patients with HFrEF and obesity may or may not derive similar benefits, and separate trials would be needed to establish this.

Mounjaro is not a replacement for standard heart failure medications. Evidence-based therapies for heart failure, including ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, diuretics, and SGLT2 inhibitors, remain the foundation of treatment. The SUMMIT trial added tirzepatide on top of guideline-directed medical therapy; it did not test it as a substitute.

Patients with active or unstable heart failure should not self-prescribe Mounjaro or any other weight-loss medication. Heart failure management requires careful fluid balance, medication titration, and regular monitoring. Introducing a new medication without specialist oversight could be harmful. The clear message from the trial is that tirzepatide shows promise in a carefully selected group of patients, managed under rigorous clinical conditions. Anyone considering this approach should discuss it with their cardiologist before making any changes to their treatment plan.

The SUMMIT trial represents a landmark moment in the understanding of how obesity treatment can influence heart failure outcomes. By demonstrating a 38% reduction in cardiovascular death or worsening heart failure events, alongside meaningful improvements in symptoms, exercise capacity, and cardiac structure, it provides robust evidence that tirzepatide can benefit patients with HFpEF and obesity.

For patients whose heart failure is driven in part by excess weight, Mounjaro may offer benefits that extend well beyond weight loss alone. The reduction in paracardiac fat, the improvement in cardiac remodelling, and the lowering of systemic inflammation all point to direct effects on the disease process itself. However, this remains a specialist area. The optimal use of tirzepatide in heart failure will require coordinated care between weight management clinicians and cardiology teams, ensuring that patients receive the full benefit of both evidence-based heart failure therapy and effective obesity treatment.

Can Mounjaro cure heart failure?

No. Heart failure is a chronic condition that can be managed but not cured with current treatments. The SUMMIT trial showed that tirzepatide can reduce the risk of worsening heart failure events and improve symptoms in patients with HFpEF and obesity, but it does not eliminate the condition. Patients will still require ongoing monitoring and, in most cases, continued heart failure medications.

Is Mounjaro approved for heart failure treatment?

No. In the United Kingdom, Mounjaro (tirzepatide) is licensed for weight management and type 2 diabetes. It is not currently approved as a treatment for heart failure. While the SUMMIT trial results are promising, regulatory approval for a heart failure indication would require further review. Any use for heart failure at present would be off-label and should involve specialist guidance.

Should I tell my cardiologist if I am taking Mounjaro?

Yes, absolutely. If you have any form of heart disease, your cardiologist needs to know about all medications you are taking, including Mounjaro. Tirzepatide can affect blood pressure, fluid balance, and body weight, all of which are relevant to heart failure management. Open communication between your weight management provider and your cardiologist ensures that your care is properly coordinated.

Can Mounjaro replace my heart failure medications?

No. Mounjaro should not be used as a substitute for standard heart failure treatments. Medications such as ACE inhibitors, beta-blockers, diuretics, and SGLT2 inhibitors form the cornerstone of heart failure therapy and have strong evidence supporting their use. In the SUMMIT trial, tirzepatide was given alongside existing heart failure treatments, not instead of them. Never stop or reduce your heart failure medications without consulting your cardiologist.

Does weight loss alone explain the heart benefits?

Weight loss is likely a major contributor, but the evidence suggests it is not the whole story. The SUMMIT trial showed reductions in paracardiac fat, left ventricular mass, and inflammatory markers that go beyond what would be expected from weight loss alone. Tirzepatide acts on both GIP and GLP-1 receptors, and these pathways may have direct effects on cardiovascular tissue. The full extent of these mechanisms is still being studied, but the data point to benefits that are partly independent of the number on the scale.